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Background: Cholinesterase inhibitors can delay the progression of Alzheimer ? s disease (AD). Several clinical trials
of the drug in moderate to severe AD have consistently reported clinically positive effects. A combining effect
with psychosocial intervention was reported in mild to moderate AD patients. Since a therapeutic approach or
rehabilitation combined with cholinesterase inhibitors for severe AD patients remains controversial, we performed a
prospective intervention for patients in Long-Term Care Health Facilities (LTCHF).
Methods: Two LTCHFs (N1, N2) were enrolled. N1 is a 126-bed facility that does not treat with donepezil but rather
with psychosocial intervention (reality orientation and reminiscence). N2 is a 150-bed facility with a 50-bed special
dementia unit, in which the physician can prescribe donepezil. On top of the similar psychosocial intervention,
rehabilitation is performed in N2. Thirty-two severe AD patients (MMSE < 6) in N1 and N2 (16 vs. 16) were compared
for the effect of donepezil (10 mg/d for 3 months) with or without psychosocial intervention (n = 8 vs. 8 for each
facility). The Vitality Index was used to assess daily activities and the introduction of rehabilitation.
Results: The response ratio (MMSE 3+) of donepezil was 37.5% in N2. The combination of donepezil with the
psychosocial intervention improved the Vitality Index total score, and Communication, Eating, and Rehabilitation
subscores (Wilcoxon, p = 0.016, 0.038, 0.023, and 0.011, respectively). Most of them were smoothly introduced to
rehabilitation, and the proportion of accidental falls decreased. Psychosocial intervention in N1 without the drug
only improved the total score (Wilcoxon, p = 0.046).
Conclusions: A combined therapeutic approach of donepezil and psychosocial intervention can have a positive
effect, even for severe patients through the introduction of rehabilitation and decreasing accidental falls. However,
these findings require replication in a larger cohort.
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The number of Alzheimer ? s disease (AD) patients con-
tinues to increase worldwide and thus the establishment
of an appropriate therapeutic approach including drug,
psychosocial intervention, and rehabilitation is necessary.
For drug treatment, cholinesterase inhibitors (ChEIs), such
as donepezil, have clinically positive effects, leading to
improvements in cognitive function for a certain duration
and delaying the progression of the disease [1]. The drug
can delay the deterioration of daily function [2], thus de-
creasing the caregivers? burden [3]. Indeed, the severity of* Correspondence: k-meg@umin.ac.jp
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unless otherwise stated.the daily functional disability is the most critical factor in
keeping AD patients living in their homes prior to place-
ment in nursing homes [4].
Most AD patients residing in nursing homes have
severe stage of disease characterized by a profound cog-
nitive loss as well as deterioration in functional abilities
[5]. Thus, the treatment of severe AD is expected to im-
prove or stabilize such symptoms [6,7]. Several clinical
trials of ChEIs in moderate to severe AD [8-11] have
consistently reported such effects. Jelic et al. [12] studied
the efficacy of donepezil for severe AD patients in 248
nursing homes, and demonstrated that donepezil treat-
ment showed stabilization or improvement across mul-
tiple outcome measures.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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psychosocial interventions are also considered in order
to optimize the function of patients. The reminiscence
approach [13] seeks to facilitate the recall of past experi-
ences and thereby improve well-being or quality of life
(QOL). Relatively well preserved remote memory in AD
[14] can provide a neurological basis to support this
approach. The reality orientation (RO) technique [13,15]
is also used, which stimulates time and place orientation,
usually by providing information regarding orientation.
It is usually used in combination with the reminiscence
approach [16,17].
We have previously reported a positive effect of com-
bined donepezil and psychosocial intervention, including
the RO with the reminiscence approach, on the patients ?
QOL [18]. However, such positive effects of the drug are
not always recognized by the patients and caregivers;
thus, leading them to discontinue the drug treatment
easily [19]. Umegaki et al. [20] surveyed the persistence of
donepezil therapy and found that only 50% of AD patients
remained on treatment after one year. The main reason
for drug withdrawal was the perceived ? ineffectiveness? of
the drugs by the patients and caregivers, which may con-
trast with their unrealistic expectations, such as ? improv-
ing? memory function.
Although benefit of psychosocial intervention such as
RO and physical reactivation program in combination
with donepezil for mild to moderate AD has been reported
[21], no such studies have been performed for patients with
severe stage of disease. Such a combined therapeutic
approach especially for severe AD patients would be better
performed at the institutes, since caregivers are also getting
old and even suffering from mild cognitive impairment in
Japan, and high-quality psychosocial intervention is not
frequently possible at home.
According to the Long-Term Care Insurance, three kinds
of institutes are available in Japan, i.e., the Long-Term Care
Health Facilities (LTCHF), Special Elderly Nursing Homes,
and Group Homes. The situations of drug treatment are
different: patients living in the latter two institutes are able
to consult doctors at other clinics to receive prescriptions.
However, after placement in the LTCHF, by law the pa-
tients can only take medicines provided by the institute,
and unfortunately expensive drugs, such as ChEIs, are not
always provided. Managers of the LTCHFs decide inde-
pendently whether or not the ChEIs are provided for eco-
nomic reasons. We believe that this is a second reason for
drug withdrawal [19].
However, we actually experienced patients with severe
AD who experienced a positive effect by the combin-
ation of donepezil and psychosocial intervention. It may
be due to the introduction of rehabilitation that was
reported to improve ADL. The aim of the study is to
investigate whether ChEIs together with psychosocialinterventions have clinically positive effects for patients
with severe AD. We hypothesized that even for LTCHF-
replacement patients with severe AD, ChEIs together
with psychosocial interventions have such effects. This
effect included improving daily activities and promoting
rehabilitation, as well as decreasing the incidence of
accidental fall. Data was collected prospectively from the
two types of LTHCFs.
Methods
LTCHF
Two LTCHFs (N1, N2), which are located in Miyagi
Prefecture, Northern Japan, were enrolled. They are run
by the same company and have a close relationship with
our research group. N1 is a 126-bed facility without done-
pezil but psychosocial intervention (reality orientation and
reminiscence) is performed. N2 is a 150-bed facility with a
50-bed special dementia unit. After the approval of done-
pezil (see below), physicians became able to prescribe
donepezil at that site. In addition to the similar psycho-
social intervention, rehabilitation is performed in N2.
Patients
Thirty-two severe patients with AD (16 in N1 and 16 in
N2) were studied. The inclusion criteria were: 1) to meet
the diagnostic criteria for probable AD according to the
NINCDS-ADRDA [22] with reference to the CT or MRI
images; 2) the scores on the Mini-Mental State Examin-
ation (MMSE) [23] were less than 6; 3) more than three
months had passed since placement in N1 or N2; and 4)
they were all able to walk with or without canes and eat
with the help of the staff.
The exclusion criteria were 1) significant neurological
signs, such as hemiparesis or swallowing disturbance; 2)
the presence of aphasia that prevented them from verbal
communication with the staff; 3) severe behavioral symp-
toms, such as delusion or delirium and wandering, that
prevented them from joining psychosocial intervention or
rehabilitation; 4) history of stroke, cerebral contusion, or
other systematic disorders that could affect central ner-
vous system function, i.e., hypothyroidism or decreases in
vitamin B1, B6, B12.
Informed consent was received from the family mem-
bers of all patients analyzed. This study was approved by
the Medical Ethics Committee of Tohoku University and
those of LTHCF N1 and N2.
Psychosocial intervention in N1 and N2
The RO and reminiscence approaches are routinely per-
formed as a group work in N1 and N2. Sixteen patients
in N1 and N2 were randomly divided into two arms, i.e.,
those who received psychosocial intervention (n = 8,
each for N1 and N2) and those who received normal care
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was also performed by a physical therapist in N2.
The characteristics of N1 and N2 facilities and the infor-
mation on the patients? demographic and clinical charac-
teristics the patients studied are shown in Table 1. Baseline
characteristics are the same through the groups.
The use of Donepezil in N2
After explanation of the study protocol, a manager at N2
agreed to employ the 3 mg, 5 mg, and 10 mg tablets of
donepezil. After confirming the absence of side effects in
response to 3 mg/day for 1 or 2 weeks, 10 mg/day of
donepezil was administered for 16 patients in N2.
Outcomes
To address the hypothesis described above, the three out-
comes below were measured pre- and post-interventions.
Post-intervention assessments were performed after a
period of 3 months. During this three-month period, the
drugs were not changed.
Vitality index
The Vitality Index [24] was used to assess daily activities
and the introduction of rehabilitation. This index is
established and validated by Toba et al., comprised of
five items, with each of them being assessed according
to 3 ratings, as follows: 1) Waking pattern (2: organized
pattern of waking, 1: requires a caregiver ? s aid occasion-
ally, 0: Never wakes voluntarily), 2) Communication (2:
vocalizes reciprocal exchanges at will, 1: responsive to
verbal stimulation, 0: no cognitive response), 3) Feeding
(2: motivated to eat, 1: passive, but eats with encourage-
ment, 0: indifferent to eating), 4) On and off toilet (2: in-
dependent or never fails to express micturition desire, 1:
does not express micturition desire consistently, 0:Table 1 Donepezil administration for AD patients in
LTCHF (n = 32) +/− Psychosocial Intervention
LTCHF-N1 LTCHF-N2
126 beds 150 beds
Dementia ward None 50 beds
Donepezil None Yes
Subjects (16 patients) (16 patients)
Usual care n 8 8
M/F 1/7 2/6









MMSE Mean (SD) 3.6 (1.2) 3.6 (1.4)
AD = Alzheimer ? s disease, LTCHF = Long-Term Care Health Facility, RO = Reality
Orientation, M =male, F = female, MMSE =Mini Mental Sate Examination.indifferent to voiding), 5) Rehabilitation and other activ-
ities (2: motivated to be rehabilitated or to be involved
in other activities, 1: passive but tries with encouragement,
0: refuses or indifferent). The staffs at the two LTCHFs re-
ceive joint uniform training in usage of the scale.
MMSE
The MMSE was used to assess general cognitive function.
Accidental falls in N2
The records of risk management in N2 before and after
donepezil administration were analyzed retrospectively.
Analyses
Analysis 1 (N1): effect of psychosocial intervention without
donepezil
Sixteen patients in N1 did not receive donepezil. Eight
patients undergoing normal care and 8 patients who
underwent the RO and reminiscence approaches were
compared to reveal the effect of psychosocial interven-
tion in the absence of donepezil.
Analysis 2 (N2): effect of psychosocial intervention
combined with donepezil
Sixteen patients in N2 received donepezil. Eight patients
undergoing normal care and 8 patients who underwent
the RO and reminiscence approaches were compared to
reveal the effect of psychosocial intervention combined
with donepezil.
Analysis 3: accidental falls (N2)
The records of risk management in N2 before and after
donepezil administration were analyzed retrospectively.
The accidents were categorized to ? Fall,? ? Bruise,? ? Drug,?
? Swallow,? ? Bed,? and ? Loss.? ? Fall? herein means fall
down on the floor during walking, ? bruise? shows any kind
of bruise on their bodies, ? drug? indicates mal-taking
medicines provided for other patients, ? swallow? means
swallowing something by mistake, ? bed? shows any kind
of troubles around the beds, and ? loss? indicates going out
of the institutes by mistake.
Non-parametric Wilcoxon matched-pairs signed-rank
tests were performed to reveal pre and post differences
for Analyses 1 and 2. The Chi-square test was used for
Analysis 3. The significance levels were all set at 0.05.
The IBM SPSS Statistics 22.0 was used.
Results
All 32 patients completed the intervention. None of the
patients exhibited acute diseases, such as pneumonia or
fever that would warrant excluding the patients from the
study protocol.
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without donepezil
Figure 1 illustrates the changes of the Vitality Index total
scores for psychosocial intervention in N1. The normal
care group showed no significant changes; however, the
psychosocial intervention group exhibited improvement
in the total scores (Wilcoxon, p = 0.046). No significant
differences were noted for the Vitality Index subscores.Analysis 2 (N2): effect of psychosocial intervention
combined with donepezil
Figure 2 illustrates the changes of the Vitality Index total
scores for psychosocial intervention combined with done-
pezil in N2. Similar to N1, the normal care group showed
no significant changes; however, the psychosocial inter-
vention group exhibited improvement in the total scores
(Wilcoxon, p = 0.016). The Vitality Index subscores of
Communication (p = 0.038), Eating (p = 0.023), and
Rehabilitation (p = 0.011) were also improved.
Table 2 notes the changes of MMSE, observed behav-
ior and cognition in 16 patients in N2. The IDs #1
through #8 received donepezil and normal care only,
and #9 through 16 received donepezil and psychosocial
intervention. Since six patients (IDs#9-11 and #14-16)
showed an increase of 3 or more MMSE points during
the 3 months follow-up (MMSE 3+ improvement), the
response ratio of donepezil was calculated as 37.5% (6/
16). Eight patients (IDs #9 through 16) were introduced
smoothly to rehabilitation and one patient (ID #9) was
discharged from N2 and returned to her home. The case











Figure 1 The normal care group showed no significant changes; how
in the total scores (Wilcoxon, p < 0.05). No significant differences were n
psychosocial intervention in LTCHF-N1.Case report
The patient (#ID 9 in Table 2) was an 89-year-old woman.
She got married when she was 24 years old. Her husband
was killed in World War II when she was 25 y. Thereafter,
she obtained a hairdresser ? s license and ran a barber shop
with her nephew. When she was 84 years old, she had
difficulty in financial management and closed her barber
shop. When she was 86 years old, she had a difficulty in
maintaining hygiene in the house. Since her room had
become verminous, a public health nurse forced her to
be placed in N2. Her MMSE score was 7. After living in
N2, she had nothing to do and just spent her time
watching TV.
Taking into consideration her past life history, we pre-
pared hair mannequins for her rehabilitation. A session
was made up of occupational therapy of hair dressing
using hair mannequins, together with reality orientation
and the reminiscence approach. We performed one hour
per day per week for 3 months. At the beginning, she
told us that she had never seen hair mannequins when
they were initially presented to her. After administration
of donepezil 5 mg/day combined with the rehabilitation,
her attention was stimulated. After 2 months, she recalled
that she had been a hairdresser and indulged in reminis-
cence about her past life. She claimed that other patients
were lacking in sanitation. Although her MMSE score was
not increased to 8, her Vitality Index increased dramatic-
ally from 1 to 6, with increases for all subscores. A phys-
ical therapist reported that she had become active and had
more attention for the rehabilitation program of standing
and gait. After three months, she was finally discharged
from N2 and returned to her home and started to live
together with her nephew.tsoperp
Psychosocial intervention
ever, the psychosocial intervention group exhibited improvement








Donepezil only (+ usual care) Donepezil + Psychosocial intervention
Figure 2 Similar to N1, the normal care group showed no significant changes; however, the psychosocial intervention group exhibited
improvement in the total scores (Wilcoxon, p < 0.05). The Vitality Index subscores of Communication, Eating, and Rehabilitation were also
improved (Wilcoxon, p < 0.05). Vitality Index changes for donepezil with or without psychosocial intervention in LTCHF-N2.
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Table 3 notes the records of risk management in N2
before (6 months, April to September 201X) and after
(October 201X~March 201X + 1) donepezil administra-
tion. The exact year was masked by the N2 staff. The
number of accidental ? Fall? decreased significantly after
donepezil administration (chi-square test at 0.05). The staff

















5 3 No changes 3
6 3 2
7 3 No changes 2
8 2 5





10 5 8 *
11 4 7 *
12 4 5
13 4 3
14 3 6 *
15 2 6 *
16 2 5 *
AD = Alzheimer ? s disease, LTCHF = Long-Term Care Health Facility, MMSE =
Mini-Mental State Examination.
*donepezil responders as shown by MMSE 3 + .developed more attention to their environment and were
more cautious in preventing falls.
Discussion and consclusions
As described in the introduction, several clinical trials of
ChEIs in moderate to severe AD have consistently reported
clinically positive effects. A combining effect with psycho-
social intervention was reported in mild to moderate AD
patients. We herein performed a combining approach for
severe AD patients in LTCJFs, and found that a combined
therapeutic approach of donepezil and psychosocial inter-
vention can have a positive effect, through the introduc-
tion of rehabilitation and decreasing accidental falls.
Effect of psychosocial intervention
The results in Analysis 1 (N1) demonstrated that psycho-
social intervention, including the RO and reminiscence
approach, was effective in the absence of donepezil admin-
istration. However, the effect was considered to be weaker
than that achieved in combination with the drug (Analysis
2 (N2)), since no significant differences were noted in the
subscores.Table 3 Risk management before/after donepezil
deployment in N2
Before After
201X.4 ~ 10 Mean
(Month)
201X.10 ~ 201X + 3. Mean
(Month)
Fall 83 11.9 38 7.6
Bruise 6 0.9 4 0.8
Drug 6 0.9 5 1.0
Swallow 0 0 1 0.2
Bed 2 0.3 0 0
Loss 0 0 0 0
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recent memory deficit can maintain intact remote mem-
ory, and that they can retain their skills. We considered
the patient ? s life history and designed a psychosocial
intervention program that was aligned with the patients ?
remote memories and skills. Good emotional relation-
ships between the patients and staff, as shown by perfect
participation rates, can enhance the positive effect of the
intervention content.
Effect of combined donepezil administration and
psychosocial intervention
The results in Analysis 2 (N2) revealed several things. The
effects of donepezil on MMSE were not apparent unless
the psychosocial intervention was added. This meant that
the drug was considered to be ? ineffective? according to
the MMSE criteria for drug responders. This was probably
due to the limitation of the dose of 10 mg/day of the drug,
and while the use of 23 mg/day donepezil is anticipated, it
is not yet permitted in Japan.
However, when the psychosocial intervention was pro-
vided in combination with the drug, the MMSE-based
response ratio was calculated as 37.5%. All patients
receiving the combined drug and psychosocial interven-
tions (IDs #9 through 16) were introduced smoothly for
rehabilitation and one patient (ID #9) was discharged
from N2 and returned to her home. Previous reports have
indicated that the drug could stimulate attention through
the frontal-parietal or basal ganglia networks [25-27]. The
preservation of function of the patients, even in the severe
stage of AD, was suspected to be activated by psychosocial
intervention, after stimulation of the patient? s attention
function by donepezil. The decreased rate of falling was
also suspected to be due to such a combined effect.
These findings also suggest that psychosocial interven-
tion could be considered to be an outcome of the done-
pezil treatment.
The financial costs of combining of drug and psycho-
social intervention might worry LTHCF managers. How-
ever, after an effective combining intervention, the ratio
of discharge of the patients to their homes might increase
like ID #9. This increased ? turnover? can obtain additional
income by the LTCI.
Limitation of the study
In this study, we could examine only two LTCHFs. In-
deed, it is not easy to involve LTCHFs for research, espe-
cially for drug treatment, since it is directly connected to
the matter of management. The N1 and N2 facilities
have close relationships with our laboratory, and patients
there have been able to undergo CT or MRI for the pur-
pose of research. Therefore, we should cautious about
the institution bias in interpreting the results. For statis-
tical analyses, we did not perform a three-way design(Institute*drug*psychosocial intervention) due to the
limited numbers of patients. Regarding the outcomes, we
used the Vitality Index, an observational scale, which is af-
fected by the skill of the observers. However, the Japanese
version is standardized and the 3 ratings are clinically
available. Also, unlikely to the Severe Impairment Battery
(SIB) [28], MMSE score is not an appropriate measure for
patients with severe AD. Potential cognitive changes
might not have been detected, which can lead to less ac-
curate results. Although the above-noted limitations were
present, we believe the results could provide useful infor-
mation on the therapeutic approach for severe AD pa-
tients in LTCHFs.Competing interests
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